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PURPOSE. To investigate the potential therapeutic benefit of intravitreally implanted dental
pulp stem cells (DPSCs) on axotomized adult rat retinal ganglion cells (RGCs) using in vitro
and in vivo neural injury models.
METHODS. Conditioned media collected from cultured rat DPSCs and bone marrow–derived
mesenchymal stem cells (BMSCs) were assayed for nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) secretion using ELISA. DPSCs or
BMSCs were cocultured with retinal cells, with or without Fc-TrK inhibitors, in a Transwell
system, and the number of surviving bIII-tubulinþ retinal cells and length/number of bIII-
tubulinþ neurites were quantified. For the in vivo study, DPSCs or BMSCs were transplanted
into the vitreous body of the eye after a surgically induced optic nerve crush injury. At 7, 14,
and 21 days postlesion (dpl), optical coherence tomography (OCT) was used to measure the
retinal nerve fiber layer thickness as a measure of axonal atrophy. At 21 dpl, numbers of Brn-
3aþ RGCs in parasagittal retinal sections and growth-associated protein-43þ axons in
longitudinal optic nerve sections were quantified as measures of RGC survival and axon
regeneration, respectively.
RESULTS. Both DPSCs and BMSCs secreted NGF, BDNF, and NT-3, with DPSCs secreting
significantly higher titers of NGF and BDNF than BMSCs. DPSCs, and to a lesser extent BMSCs,
promoted statistically significant survival and neuritogenesis/axogenesis of bIII-tubulinþ
retinal cells in vitro and in vivo where the effects were abolished after TrK receptor blockade.
CONCLUSIONS. Intravitreal transplants of DPSCs promoted significant neurotrophin-mediated
RGC survival and axon regeneration after optic nerve injury.
Keywords: dental pulp stem cells, mesenchymal stem cells, axon regeneration,
neuroprotection, cell transplantation
Trauma is the most common cause of central nervous system(CNS) injury with, in America alone, 11,000 people a year
suffering a spinal cord injury (SCI),1 80,000 a year suffering
severe traumatic brain injury,2 and between 0.5% and 5.0% of
head injuries resulting in traumatic optic neuropathy.3 Chronic
degenerative diseases are another leading cause of CNS damage,
including glaucoma, a condition that affects retinal ganglion
cells (RGCs) and is the second leading cause of blindness
worldwide.4 Lost neurons are not replaced, and severed axons
do not regenerate after CNS injury, and, thus, recovery of lost
sensory and motor function is severely limited.
The failure of CNS axons to regenerate after injury is partly
attributed to a nonpermissive trophic environment composed
of both a paucity of neurotrophic growth factors and an
abundance of axon growth inhibitory molecules.5 Neurotro-
phins, a class of neurotrophic factors (NTF), include nerve
growth factor (NGF), brain-derived neurotrophic factor
(BDNF), and neurotrophin-3 (NT-3). They promote regenera-
tion of injured axons and the survival of axotomized neurons
after binding to the tropomyosin receptor kinase-A, -B, and -C
(TrK) receptors, respectively.6 Inhibitory ligands, which derive
from degenerate myelin7,8 and scar tissue6,9 in CNS lesion sites,
induce receptor-mediated growth cone collapse of regenerating
injured axons.
Thus, inducing changes to the microenvironment of injured
neurons/axons to promote neuronal survival and disinhibited
axon regeneration represents a potential treatment approach.
The delivery of NTF to neuron somata rather than to the lesion
site has proved a successful therapeutic strategy.6 For example,
several studies have successfully promoted RGC survival after
intravitreal delivery of exogenous NTF to the vitreous after
optic nerve injury.10,11 To promote a significant effect,
however, repeated injections of NTF combinations are neces-
sary, which are highly invasive for the patient, indicating that a
continuous delivery mechanism is preferred.12,13 Moreover,
bolus administration of neurotrophins act to downregulate the
TrK receptors,14,15 an effect that may be avoided by opting for a
lower but continuous delivery regimen. Cellular therapy is
regarded as a promising means of altering the trophic
environment of damaged CNS neurons, such as RGCs. This
strategy has met with some success; for example, using
intravitreally administered fibroblasts genetically altered to
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release NTF combinations16 after optic nerve crush (ONC).
ONC acts as an effective model of CNS injury in general and
retinal neuron disease in particular.6
As an alternative to engineered cells, naturally occurring
stem cells have been used to promote CNS repair, providing a
source of either replacement neurons17,18 or NTF combina-
tions that promote endogenous neuron survival and axon
regeneration by altering the local trophic microenvironment.19
Stem cell–based CNS studies have increasingly used NTF-
secreting bone marrow–derived mesenchymal stem cells
(BMSCs) as a cellular therapy.20,21 Moreover, BMSC-conditioned
medium is neuroprotective in culture,22 and intravitreal BMSC
transplantation is neuroprotective for RGCs after optic nerve
injury23 and glaucoma.24
However, an emerging alternative stem cell source is the
dental pulp, which contains self-renewing and pluripotent
stem cells.25 Dental pulp stem cells (DPSCs) are isolated from
the dental pulp of both infant and adult mammalian teeth with
relative ease of access and few ethical hurdles. Thus, DPSCs
represent a potential autologous and allogeneic cellular
therapy for CNS injury, particularly because recent evidence
suggests that they are more potent than BMSCs at promoting
functional recovery after spinal cord injury.21 Although largely
uncharacterized, a few studies have explored their potential to
play a direct role in neuronal replacement owing to their
neural crest origin.26 DPSCs differentiate into neurons under
defined in vitro conditions27,28 and their integration into the
CNS after transplantation has been described.29
Less focus has been given to exploiting DPSCs as an indirect
NTF therapy (i.e., using DPSC-derived NTF to promote
endogenous CNS neuron survival and axon regeneration).
DPSCs express mRNA for NGF, glial cell line–derived neuro-
trophic factor (GDNF), and BDNF.30–32 When transplanted into
the hippocampus, DPSCs secrete ciliary neurotrophic factor
(CNTF), VEGF, NGF, and FGF-2,33 which could explain the
findings of Sakai et al,21 who demonstrated some functional
recovery after complete transection of the spinal cord by
transplanting DPSCs into the lesion site. The authors witnessed
both an improvement in locomotory BBB34 (Basso, Beattie,
Bresnahan) scores and axon growth into the cell implant and
across the lesion site at greater levels than after BMSC
transplant. This observation, along with the greater expression
of neurotrophic factor mRNA by DPSCs compared with
BMSCs21 indicates that DPSCs produce higher titers of
neurotrophic factors compared with BMSCs. DPSCs transplant-
ed into a cerebral infarct site after middle cerebral artery
occlusion also promoted significant recovery in forelimb
sensorimotor function. The transplanted DPSCs differentiated
into astrocyte-like cells, suggesting that DPSCs contributed to
neural regeneration as supportive cells through NTF secre-
tion.35
In the present study, we investigated the neuroprotective
and axogenic properties of primary adult rat DPSCs for
axotomized RGCs. We carried out in vitro coculture studies
of DPSCs with primary adult rat retinal cultures and compared
bIII-tubulinþ retinal cell survival and neurite outgrowth in
these cultures with that in BMSC/retinal cell cocultures. Using
specific Fc-TrK fusion protein blockers of the neurotrophin
receptors, we determined a bIII-tubulinþ retinal cell neuropro-
tective and axogenic role for DPSC-derived neurotrophins. In
addition, we used an in vivo model of ONC injury to determine
the effects of intravitreal stem cell transplantation on Brn-3aþ
RGC survival and axon regeneration. Our findings demonstrate
that DPSCs promote RGC survival and axon regeneration
through the secretion of neurotrophins to a greater extent than
do BMSCs, and, hence, we propose that DPSCs have potential
as a cellular therapy to treat RGC injury and degenerative
disease.
METHODS
All reagents were purchased from Sigma (Poole, UK) unless
otherwise specified.
DPSC Isolation and Culture
Three adult male Sprague-Dawley rats weighing 170 to 200 g
(Charles River, Kent, UK) were housed under Home Office
guidelines and killed by ‘‘Schedule 1 Methods’’ before
extraction of both upper and lower incisors. The dental pulp
was removed under sterile conditions in Dulbecco’s Modified
Eagle’s Medium (DMEM) (Life Technologies, Gibco, Paisley,
UK) supplemented with 1% penicillin/streptomycin (P/S),
sliced into 1-mm3 fragments and incubated in 4 mL 0.25%
trypsin-EDTA for 30 minutes at 378C. Trypsin was inactivated
by adding an equal volume of DMEM containing 1% P/S and
10% fetal bovine serum (FBS). A single cell population was
obtained by passing the cell suspension through a 70-lm cell
strainer (BD Biosciences, Oxford, UK), which was centrifuged
at 150g for 5 minutes. Cell pellets were resuspended in DMEM
containing 1% P/S and 10% FBS and seeded into T25 flasks
(Corning, Amsterdam, The Netherlands) in a total volume of 5
mL. Cultures were maintained at 378C in 5% CO2 and medium
was changed 24 hours after seeding, and every 3 days
thereafter, with cells passaged when 80% confluent using
0.05% trypsin. Each animal provided stem cells for separate
cultures to supply conditioned medium for the ELISA before
cells from three cultures were pooled for the in vitro
coculture/in vivo transplantation experiments.
BMSC Isolation and Culture
BMSCs were isolated from femurs removed from the same
animals described above. In sterile conditions, the ends of the
femurs were detached, and the bone marrow flushed with 10
mL DMEM. Cell aspirates were centrifuged at 150g for 5
minutes before cells were resuspended in DMEM containing
1% P/S and 10% FBS. Cell suspensions were seeded into T25
flasks in a total volume of 5 mL. Cultures were maintained at
378C in 5% CO2 and medium was changed 24 hours after
seeding and every 3 days thereafter, with cells passaged when
80% confluent. Each animal provided stem cells for separate
cultures to supply conditioned medium for the ELISA before
cells from three cultures were pooled for the in vitro
coculture/in vivo transplantation experiments.
NGF/BDNF/NT-3 ELISA
To quantify the neurotrophins produced by BMSCs and DPSCs,
conditioned medium was taken from cells at passages two to
four, cultured for 48 hours, and assayed using EMAX Immuno-
assay kits (Promega, Southampton, UK) for rat NGF, BDNF, and
NT-3, as well as CNTF (R&D Systems, Abingdon, UK),
according to the manufacturers’ instructions. Briefly, a
standard curve was constructed using the provided neurotro-
phin standards, and test samples of conditioned medium at
varying dilutions were run in duplicate after acid treatment,
with neurotrophin concentrations extrapolated from the
standard curve.
Retinal Cell Coculture
Cell culture 24-well plates (BD Biosciences) were coated for 60
minutes with 100 lg/mL poly-D-lysine and then for 30 minutes
with 20 lg/mL laminin. After terminal anesthesia, eyes were
removed from three male Sprague-Dawley rats weighing 170 to
200 g (Charles River) and the retinae minced in 1.25 mL papain
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(Worthington Biochem, Lakewood, NJ) containing 62.5 lL
DNase I (Worthington Biochem) and incubated for 90 minutes
at 378C. The retinal cell suspension was centrifuged at 300g for
5 minutes and the pellet resuspended in a solution containing
1.35 mL EBSS (Earle’s balanced salt solution; Worthington
Biochem), 150 lL reconstituted albumin ovomucoid inhibitor
(Worthington Biochem), and 75 lL DNase I. The retinal cell
suspension was layered onto 2.5 mL of albumin ovomucoid
inhibitor to form a discontinuous density and centrifuged at
70g for 6 minutes. The resulting retinal cell pellet was
resuspended in 1 mL supplemented Neurobasal-A (24.2 mL
Neurobasal-A [Gibco] supplemented with 500 lL B27 supple-
ment [Life Technologies, Invitrogen, Paisley, UK], 62.5 lL L-
glutamine [200 mM; Invitrogen], and 125 lL gentamycin
[Invitrogen]) and seeded at a density of 125,000 cells/800 lL in
each well of the 24-well plate.
DPSCs and BMSCs were used at passages two to four and
plated at a density of 50,000 cells/200 lL into a 0.4-lm porous
cell culture insert (Millicell; Millipore, Watford, UK) that was
inserted into each of the 24 wells containing retinal cells, to
give a total volume of 1 mL of medium per well. Particular
wells containing retinal cell cultures were also treated with 5
lg/mL Fc-TrKA, Fc-TrKB, and/or Fc-TrKC (single or combina-
torial treatments; R&D Systems) fusion TrK-specific protein
inhibitors,36 as well as the general kinase inhibitor k252a (50
nM). A combination of recombinant human NGF, BDNF, and
NT-3 was also added to selected retinal cell cultures (all at 60
ng/mL) to act as a positive control.
Cocultures were incubated for 4 days at 378C before
immunocytochemical staining of retinal cells for bIII-tubulin.
All experiments were repeated on three separate occasions.
Each of the treatment groups in each of the three experimental
runs comprised three replicate wells containing retinal cells
harvested from one animal. The DPSCs/BMSCs tested in each
of the three experimental runs represented pooled cells from
three animals.
In Vivo Experimental Design
The experimental design for the in vivo experiment is detailed
in Figure 1. Briefly, 18 animals (36 eyes) were divided into six
groups of six eyes. The first six animals (12 eyes) received a
bilateral ONC and DPSC transplanted intravitreally, living cells
in the right eye and dead cells in the left. The next six animals
(12 eyes) received the same allocation, but BMSCs were
transplanted instead of DPSCs. The final six rats (12 eyes)
received a unilateral ONC to the left eye, whereas the right eye
served as an intact control. Both eyes in each animal of this
group received an intravitreal control injection of PBS instead
of cell suspension to control for the transplantation procedure.
Optical coherence tomography (OCT) was used to measure
retinal nerve fiber layer thickness (RNFL) of animals every 7
days, including 7 days before the surgery and excluding the day
of the surgery. Animals were killed at 21 days after ONC/cell
transplantation.
Animals
All animal procedures were performed in strict accordance to
the UK Home Office Animals Scientific Procedures Act, 1986,
ARVO statement for the use of animals in ophthalmic and
vision research, and approved by the University of Birmingham
Ethical Review Sub-Committee. Eighteen adult female Sprague-
Dawley rats weighing 150 to 200 g (Charles River) were
housed in conditions of 218C and 55% humidity under a 12-
hour light and dark cycle, given food/water ad libitum, and
were under constant supervision from trained staff. Anesthesia
was induced with 5% isoflurane/1.5 L per minute O2 (National
Veterinary Supplies, Stoke, UK) and was maintained at 3.5%
during surgery.
Surgical Procedures
Following anesthetic induction as described above, a subcuta-
neous injection of buprenorphine (0.1 mL/100 g; National
Veterinary Supplies) was given and the animal secured in a
head-holding frame. Intraorbital ONC was performed as
described previously.37 Briefly, the optic nerve was surgically
exposed and crushed using forceps 1 mm posterior to the
lamina cribrosa with no damage to retinal blood vessels.
Immediately after ONC, a glass micropipette, produced in-
house from a glass capillary rod (Harvard Apparatus, Eden-
bridge, Kent, UK) using a Flaming-Brown micropipette puller
(Sutter Instruments, Novato, CA) preloaded with 150,000 cells
FIGURE 1. Experimental design used for in vivo experiment. Time line of the in vivo experiment detailing the times when the OCT recordings and
tissue collections were undertaken, in relation to the day of the ONC and DPSC/BMSC transplantation.
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suspended in 5 lL of PBS, was used to inject living or dead cells
(killed by heating for 30 minutes at 808C; or PBS alone in
controls) into the vitreous of the eye. After surgery, animals
were placed in heated recovery cages and monitored for
recovery of normal behavior, after which they were returned to
home cages.
OCT of RNFL
Every 7 days, including 7 days before the surgery but excluding
the week of the surgery (Fig. 1), OCT was performed on rats
(anesthetized as detailed above) using a Spectralis HRA3
confocal scanning laser ophthalmoscope (Heidelberg Engi-
neering, Heidelberg, Germany). OCT images were taken of the
retina around the optic nerve head and the in-built software
was used to segment the gathered images and quantify the
RNFL thickness.
Tissue Preparation
At 21 dpl, animals were given an intraperitoneal injection of 1
mL sodium pentobarbital (National Veterinary Supplies) and
perfused intracardially with 4% paraformaldehyde (PFA; TAAB,
Reading, UK) in PBS while under terminal anesthesia. Eyes and
optic nerves were removed and immersion fixed in 4% PFA in
PBS for 2 hours at 48C before cryoprotection in 10%, 20%, and
30% sucrose solution in PBS for 24 hours with storage at 48C.
Eyes and optic nerves were then embedded using optimal
cutting temperature embedding medium (Thermo Shandon,
Runcorn, UK) in peel-away mold containers (Agar Scientific,
Essex, UK) by rapid freezing under crushed dry ice and were
stored at 808C. After embedding, eyes and optic nerves were
sectioned on a cryostat microtome (Bright, Huntingdon, UK) at
228C at a thickness of 20 lm and 15 lm, respectively, and
mounted on positively charged glass slides (Superfrost Plus;
Fisher Scientific, Pittsburgh, PA). Longitudinal optic nerve and
parasagittal eye sections were left to dry on slides overnight at
378C before storage at 308C. Optic nerve sections were
chosen at random for analysis, whereas eye sections were
chosen with the optic nerve head visible.
Immunohistochemistry
Mounted tissue sections were equilibrated to room tempera-
ture, hydrated in PBS for 23 5 minutes, permeabilized in 0.1%
Triton X-100 in PBS for 20 minutes at room temperature, and
washed for 2 3 5 minutes in PBS before isolation with a
hydrophobic PAP pen (Immedge pen; Vector Laboratories,
Peterborough, UK). Nonspecific protein-binding sites in
sections were blocked by incubation in blocking buffer (75
lL; 0.5% bovine serum albumin [g/mL], 0.3% Tween-20, 15%
normal goat/donkey serum [Vector Laboratories] in PBS) in a
humidified chamber for 30 minutes at room temperature and
then sections were drained and incubated with primary
antibody diluted in antibody-diluting buffer (ADB; 0.5% bovine
serum albumin, 0.3% Tween-20 in PBS) overnight at 48C. The
following day, slides were washed for 3 3 5 minutes in PBS.
Tissue sections were then incubated with secondary antibody
diluted in ADB for 1 hour in a hydrated incubation chamber at
room temperature. After 1 hour, slides were washed for 33 5
minutes in PBS, mounted in Vectorshield mounting medium
containing 40,6-diamidino-2-phenylindole (DAPI) (Vector Labo-
ratories) and stored at 48C before microscopic analysis.
Antibodies used in this staining are detailed in the Table.
Immunocytochemistry
Cells in 24-well plates were fixed in 4% PFA for 10 minutes,
washed for 3310 minutes of PBS, blocked in blocking solution
as described above for 20 minutes, and incubated with primary
antibody diluted in ADB for 1 hour at room temperature. After
1 hour, cells were washed for 3310 minutes in PBS, incubated
with the secondary antibody diluted in ADB for 1 hour at room
temperature, washed for 3 3 10 minutes in PBS, mounted in
Vectorshield mounting medium containing DAPI, and stored at
48C. Antibodies used in this staining are detailed in the Table.
Microscopy and Analysis
Fluorescently stained sections were analyzed by an operator
blinded to treatment groups, using a Zeiss Axioplan-2
fluorescent microscope (Carl Zeiss, Ltd., Hertfordshire, UK).
For immunocytochemistry, all retinal cells that were positive
for the neuronal marker bIII-tubulin,38 with or without
neurites, were counted over each entire well of the 24-well
plate, with the number of bIII-tubulinþ retinal cells with
neurites and the total number of bIII-tubulinþ retinal cells
being recorded. Neurite outgrowth was measured in images
taken at320 magnification using an Axiocam HRc camera (Carl
Zeiss, Ltd.). Each well was divided into nine equal sectors and
the length of the longest neurite per bIII-tubulinþ retinal cell in
each sector was measured using Axiovision software (Carl
Zeiss, Ltd.).
For immunohistochemistry, Brn3aþRGCs39 were counted in
20-lm-thick sections of the retina, along a 250-lm linear region
of the ganglion cell layer, stretching out horizontally on either
side of the optic nerve. Four sections per retinae and six
retinae from six different animals per treatment group were
quantified.
For in vivo quantification of axon regeneration, 320
magnification images were taken of growth-associated pro-
tein-43 (GAP-43)–stained longitudinal sections of the optic
nerves and composite images were constructed in Photoshop
CS3 (Adobe Systems, Inc., San Jose, CA). Photoshop CS3 was
used to contrast-enhance selected images to improve the
visibility of GAP-43þ axons, with all manipulations kept
identical across the treatment groups. RGC axon regeneration
in vivo was quantified in the composite images by counting the
number of GAP-43þ axons extending across a line set at 908
across the optic nerve at 100, 200, 400, 800, and 1200 lm
distal (toward the chiasm) to the center of the crush site
(identified by lamininþ staining) of six optic nerves from six
different animals per treatment group and three sections per
optic nerve. By measuring the diameter of the nerve at each
measurement point, the number of axons/mm width was
TABLE. Antibodies Used in Immunohistochemistry and Immunocyto-
chemistry
Antigen Dilution Supplier Catalog No.
BDNF 1:200 Promega G1641
NT-3 1:200 Millipore AB1780SP
GFAP 1:200 Sigma G9269
RBMY 1:100 Santa Cruz,
Santa Cruz, CA
SC-14572
bIII-tubulin 1:500 Sigma T8660
Brn3a 1:200 Santa Cruz SC-31984
GAP-43 1:400 Zymed Laboratories,
San Francisco, CA
33-5000
Laminin 1:200 Sigma L9393
Mouse IgG,. Fluor 488 1:400 Molecular Probes,
Paisley, UK
A-21202
Rabbit IgG, Fluor 488 1:400 Molecular Probes A-21206
Rabbit IgG, Fluor 594 1:400 Molecular Probes A-21207
Goat IgG, Fluor 594 1:400 Molecular Probes A-11058
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calculated. This value was then used to derive
P
ad, the total
number of axons extending distance d in an optic nerve with
radius r using the formula described by others40:
X
ad ¼ pr2 3 average number of axons=mm width
section thickness ð0:015 mmÞ :
Statistics
All statistical tests were performed using SPSS 17.0 (IBM SPSS,
Inc., Chicago, IL) and data were presented as mean 6 SEM.
The Kolmogorov-Smirnov test was used to ensure all data were
normally distributed before parametric testing using a one-way
ANOVA with a Tukey post hoc test. Statistical difference was
considered significant at P values less than 0.05.
RESULTS
DPSCs Secreted NGF, BDNF, and NT-3
DPSCs secreted NGF (281 6 68 pg/24 h/105 cells), BDNF
(1600 6 338 pg/24 h/105 cells), and NT-3 (270 6 53 pg/24 h/
105 cells) in culture, as analyzed by ELISA (Fig. 2). These
neurotrophic titers were 2- to 3-fold higher than those detected
in conditioned medium from BMSC cultures (91.3 6 24.2, 749
6 237, 166 6 46 pg/24 h/105 cells, respectively) with the
differences for NGF and BDNF being statistically significant (P
< 0.05). CNTF was undetectable in all samples tested (data not
shown).
DPSCs Promoted bIII-TubulinþRetinal Cell Survival
and Neuritogenesis in a Coculture Assay
DPSCs promoted a significant (P < 0.05) increase in the
survival of cocultured bIII-tubulinþ retinal cells (340.3 6 10.4
cells/well) compared with retinal cells cultured alone (92.7 6
20.8 cells/well), cocultured with BMSCs (227 6 27.6 cells/
well) or treated with recombinant human NGF, BDNF, and NT-3
(278.7 6 8.0 cells/well; Fig. 3).
DPSCs also promoted a significant (P < 0.05) increase in the
number of bIII-tubulinþ retinal cells with neuritis, as well as the
neurite length (161.6 6 5.8 lm, 172.7 6 9.5 lm, respectively;
Fig. 3), compared with either retinal cells cultured alone (36.0
6 5.2 lm, 22.7 6 5.2 lm) or cocultured with BMSCs (137.8 6
2.3 lm, 91.0 6 12.6 lm; Fig. 3). The combination of
recombinant human NGF, BDNF, and NT-3 significantly (P <
0.05) increased the number of bIII-tubulinþ retinal cells with
neurites (142.3 6 10.1 cells/well), as well as the neurite length
(155.4 6 27.4 lm) compared with retinal cells cultured alone,
or when cocultured with BMSCs (P > 0.05).
Fc-TrK Receptor Blockers Attenuated the Survival
and Neuritogenic Effects of DPSCs
The number of bIII-tubulinþ retinal cells surviving in DPSC
cocultures (340.3 6 10.4 cells/well) was significantly (P <
0.05) decreased after treatment with Fc-TrKA (182.7 6 16.4
cells/well), Fc-TrKB (165.3 6 3.0 cells/well), and Fc-TrKC (193
6 17.1 cells/well) used alone or in combination (99.3 6 9.0
cells/well; Fig. 3). In BMSC cocultures, bIII-tubulinþ retinal cell
survival (227.0 6 27.6 cells/well) was significantly (P < 0.05)
reduced with Fc-TrKA (145.3 6 5.4 cells/well), Fc-TrKB (138.0
6 5.5 cells/well), or Fc-TrKA, -B, and -C together (85.7 6 17.1
cells/well), but not after adding Fc-TrKC (158.3 6 10.3 cells/
well; P > 0.05).
Fc-TrKA, -B, and -C used individually, significantly (P < 0.05)
decreased both the number of neurite-bearing cells (84.0 6
9.5, 64.0 6 5.3, 74.7 6 12.9 cells/well, respectively) as well as
the length (112.4 6 9.1 lm, 86.7 6 9.0 lm, 103.7 6 1.1 lm,
respectively) of neurites in DPSC/retinal cell cocultures
compared with DPSCs/retinal cells cocultured without inhib-
itors (Fig. 3). Combining the Fc-TrK inhibitors further
attenuated the number of bIII-tubulinþ retinal cells with
neurites (38.0 6 4.9 cells/well) as well as neurite length
(53.9 6 7.9 lm) seen in the DPSC/retinal cell coculture.
Similar effects, although less exaggerated, were seen in the
BMSC/retinal cell cocultures. Accordingly, a statistically signif-
icant (P < 0.05) reduced neurite length from 137.8 6 2.3 lm
to 65.4 6 2 lm was seen only when the three neurotrophin
inhibitors were combined in the BMSC/retinal cell coculture,
but not when each inhibitor was used in isolation.
DPSC Transplants Preserved RNFL Thickness for
Up to 14 Days After ONC Injury
All transplanted animals and eyes survived the experiment
with no observable adverse effects.
FIGURE 2. NGF, BDNF, and NT-3 secretion from DPSCs and BMSCs. DPSC- and BMSC-conditioned medium, collected after 48 hours of cell culture,
was assayed using specific ELISAs for rat NGF, BDNF, and NT-3 (n¼ 3; black lines indicate significant difference at P < 0.05).
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Because the RNFL comprises RGC axons that pass over the
surface of the retina toward the optic disk, RNFL thickness was
used to measure postaxotomy RGC axonal atrophy and did not
significantly (P < 0.05) change in uninjured animals over time.
In ONC animals, RNFL thickness was reduced significantly (P
< 0.05) from 49.3 6 2.1 lm to 30.2 6 1.5 lm at 7 dpl, 21.4 6
1.6 lm at 14 dpl, and 17.0 6 1.2 lm at 21 dpl (Fig. 4). Animals
receiving dead DPSC/BMSC transplantations showed a similar
thinning in RNFL thickness with no significant (P < 0.05)
difference from ONC alone. However, there was no significant
(P < 0.05) RNFL thinning at 7 dpl in animals that were injected
with living DPSCs/BMSCs (46.2 6 1.4 lm, 46.0 6 2.1 lm,
respectively) compared with intact animals at 7 dpl (45.7 6
1.2 lm), indicating a neuroprotective effect of the DPSCs. At
14 dpl, RNFL thickness of the DPSC-transplanted animal had
decreased to 32.8 6 0.7 lm, which was significantly (P <
0.05) lower than that in intact animals (45.4 6 0.2 lm), but
still significantly (P < 0.05) higher than in untreated animals
(21.4 6 1.6 lm). This is in contrast to animals that received
BMSCs in which RNFL thickness decreased to 28.5 6 1.6 lm
by 14 dpl, which was not significantly (P > 0.05) different from
untreated animals. By 21 dpl, the RNFL in animals receiving
either DPSCs or BMSCs (24.0 6 1.3 lm, 22.0 6 1.8 lm,
respectively) had reduced to a thickness not significantly (P >
0.05) different from that seen in untreated animals at 21 dpl
(17.0 6 1.2 lm).
Transplanted Intravitreal DPSCs Survived In Vivo
for 21 Days
Viable DPSCs were detected in the vitreous at 21 dpl associated
with elevated levels of BDNF and NT-3 in the retina at 21 dpl
compared with eyes transplanted with dead DPSCs (Fig. 5).
Activated glial fibrillary acidic proteinþ (GFAP) glia were also
observed in eyes transplanted with DPSCs but not with dead
DPSCs. Similar findings were observed with BMSCs (data not
shown).
Intravitreal DPSC Transplants Protected RGCs
From Death After ONC
Intravitreal DPSC transplantation after ONC significantly
increased (P < 0.05) RGC survival at 21 dpl (27.9 6 2.0
RGCs/mm of retina) compared with animals receiving BMSC
FIGURE 3. Effects of DPSCs and BMSCs on bIII-tubulinþ retinal cells. In vitro bIII-tubulinþ retinal cells, cultured either alone (Ai), with exogenous
neurotrophins (Aii), with BMSCs (with or without TrK inhibitors [Aiii, Aiv, respectively]) or with DPSCs (with or without TrK inhibitors [Av, Avi,
respectively]). All images are representative of the entire culture, nine separate culture wells per treatment with every three wells using a different
animal (scale bars: 100 lm). The number of surviving bIII-tubulinþ retinal cells (B), number of bIII-tubulinþ retinal cells with neurites (C), and the
length of the longest bIII-tubulinþ retinal cell neurite (D) when retinal cells were cocultured with BMSCs (blue bars), DPSCs (red bars), exogenous
neurotrophins (green bars), or alone (purple bars). Black lines indicate significant difference at P < 0.05. The effects of TrKA, -B, and -C Fc-
inhibitors, as well as K252a on bIII-tubulinþ retinal cell survival and neuritogenesis in DPSC and BMSC cocultures are shown (points marked with an
asterisk indicate significant difference from uninhibited cultures at P < 0.05).
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transplants (16.2 6 1.3 RGCs/mm of retina), dead DPSC
transplants (5.7 6 0.6 RGCs/mm of retina), or ONC alone (6.9
6 1.1 RGCs/mm of retina; Fig. 6), as determined by Brn3aþ
staining. Nonetheless, RGC survival after BMSC transplantation
was also significantly (P < 0.05) greater than in animals
receiving dead BMSC transplants (8.4 6 1.1 RGCs/mm of
retina) or in untreated animals, demonstrating that BMSCs
exerted some neuroprotective effect for RGCs, although at a
lower level than did DPSCs.
Intravitreal DPSC Transplants After ONC-Promoted
RGC Axon Regeneration
At distances of 100, 200, 400, 800, and 1200 lm distal to the
crush site, the number of regenerating GAP-43þ RGC axons
was significantly (P < 0.05) increased (284.7 6 33.0, 221.0 6
23.3, 214.5 6 26.0, 181.9 6 42.0, 115.9 6 25.6 axons/nerve,
respectively) after intravitreal transplantation of DPSCs com-
pared with BMSCs (133.7 6 21.1, 115.9 6 25.0, 85.4 6 19.8,
77.2 6 10.4, 50.4 6 10.3 axons/nerve, respectively), dead
DPSCs (68.7 6 19.6, 54.4 6 11.0, 42.7 6 8.6, 31.7 6 15.3, 9.5
6 4.9 axons/nerve, respectively), or untreated (78.1 6 16.9,
48.6 6 7.2, 34.9 6 6.0, 11.7 6 3.7, 2.5 6 1.5 axons/nerve,
respectively; Fig. 7) at 21 dpl. BMSC-transplanted animals had
significantly (P < 0.05) greater numbers of regenerating RGC
axons in the distal optic nerve compared with untreated
animals at all distances and significantly (P < 0.05) greater
numbers of regenerating axons compared with animals
receiving dead BMSCs (59.7 6 6.5, 45.5 6 8.6, 46.7 6 9.2,
40.4 6 9.9, 18.2 6 5.3 axons/nerve, respectively) at distances
of 100 and 200 lm distal to the crush site.
DISCUSSION
This study provides evidence that DPSCs, through secretion of
neurotrophins, significantly increase both survival and neurito-
genesis of primary adult rat bIII-tubulinþ retinal cells in an in
vitro coculture assay. Furthermore, when transplanted into the
vitreous body of adult rats after ONC, DPSCs significantly
promote Brn-3aþ RGC survival and axon regeneration. Note-
worthy, the neuroprotective and proregenerative effects of
DPSCs seen in these in vitro and in vivo models was greater
than that observed with BMSCs, which can be related to their
enhanced neurotrophic profile as determined by ELISA and
suggests that DPSCs have a greater potential to repair CNS/
retinal injury.
Our findings are consistent with a recent study that
demonstrated greater positive effects of locally transplanted
DPSCs on locomotory recovery from SCI than did BMSC
transplants.21 Moreover, the improvement in locomotory
function after cell transplantation into an SCI site occurred in
the absence of local neuronal differentiation, suggesting that
the transplanted cells acted indirectly, creating a more
FIGURE 4. RNFL thickness after ONC. OCT images of retina from an uninjured rat (A) and a rat 21 days after ONC (B) are shown with red lines
outlining the RNFL. OCT images were taken of the retinal section surrounding the optic nerve head, indicated by the green line (C). Images are
representative of the six animals used in each treatment group (scale bar: 200 lm). The graph (D) depicts changes in RNFL thickness over time for
uninjured optic nerves (orange line), DPSC transplanted eyes (red line), BMSC transplanted eyes (blue line), dead DPSC transplanted eyes (dashed
red line), and dead BMSC transplanted eyes (dashed blue line). Points marked with an asterisk indicate significant difference from untreated/dead
cell transplanted animals at P < 0.05.
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supportive trophic environment for endogenous axonal
sprouting/growth.
Our finding that DPSCs enhanced bIII-tubulinþ retinal cell
survival and neurite outgrowth in a coculture model can be
attributed to the release of soluble factors, as the two
populations of cells were separated by a porous membrane.
Moreover, the use of specific Fc-TrK inhibitors enabled us to
identify DPSC-derived NGF, BDNF, and NT-3 as important NTFs
responsible for this neuroprotective and neuritogenic effect.
Use of individual Fc-TrK inhibitors as opposed to combined,
demonstrated that NGF, BDNF, and NT-3 each had equally
important neuroprotective and neuritogenic effects. The ELISA
measurements confirmed the secretion of these factors by the
DPSCs, corroborating previous work showing that DPSCs
FIGURE 5. DPSC survival and trophic effects 21 days after ONC/cell transplantation. Immunohistochemically stained 20-lm-thick parasagittal
sections of retina and vitreous, stained for BDNF (A, B), NT-3 (C, D), GFAP (E, F), and Y chromosome (G) 21 days after ONC and intravitreal
transplantation of DPSCs (A, C, E, G) or dead DPSCs (B, D, F) with outer nuclear layer (ONL), inner nuclear layer (INL), and ganglion cell layer
(GCL) labeled. A negative control with the primary antibodies omitted is included (F). All images are representative of the two images per section,
four sections per retina, six retinae from six different animals per treatment group. DAPI was used as a nuclear counterstain (scale bars: 100 lm).
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express multiple NTF mRNA, including neurotrophins.21,31–33
Interestingly, BMSCs exhibited a less potent neurotrophic
effect on cultured bIII-tubulinþ retinal cells than DPSCs; and
this novel observation can be related to their reduced
neurotrophin profile. Of note, K252a, a nonspecific blocker
of TrK receptors, as well as other protein kinases, further
reduced the neuritogenic effect of DPSCs/BMSCs compared
with Fc-Trk blockade. These findings suggest that other TrK-
FIGURE 6. RGC survival 21 days after ONC/cell transplantation. Immunohistochemically stained 20-lm-thick parasagittal sections of retina, stained
for bIII-tubulin (green) and Brn3a (red) in intact animals (Ai) and 21 days after ONC (Aii) and intravitreal transplantation of dead BMSCs (Aiii), dead
DPSCs (Aiv), living BMSCs (Av), and living DPSCs (Avi) with ONL, INL, and GCL labeled. All images are representative of the two images per
section, four sections per retina, six retinae from six different animals per treatment group. DAPI was used as a nuclear counterstain (scale bars: 100
lm). In (B), the number of Brn3aþ RGCs, counted in a 1-mm region of the GCL 21 dpl is shown. Black lines indicate significant difference at P <
0.05.
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independent growth factors may also mediate the neurotroph-
ic effects of DPSCs/BMSCs. Indeed, DPSCs express other
trophic factors, such as GDNF.30 By contrast, neuroprotection
was similarly reduced after both K252a and TrK blockade,
suggesting that the stem cell–derived neurotrophins NGF,
BDNF, and NT-3 were the primary RGC neuroprotective agents.
Axotomy interrupts the supply of retrogradely transported
neuroprotective NTF and, in many cases, the neuron subse-
quently dies, with RGCs being exquisitely sensitive to such
adversities.10,41 Neurotrophins also play an important role in
growth cone formation/elongation and are relatively abundant
in the peripheral nervous system compared with the CNS,
possibly explaining the disparity between the axon regenera-
tive response of the two sites. DPSCs/BMSCs provide an
alternative source of NTF for axotomized RGCs, protecting
them from death and promoting RGC axogenesis.
After ONC, RGCs begin dying from 7 dpl42 with 80% to 90%
dead by 2 to 3 weeks,6,10,41 thus making this a suitable in vivo
model to assess DPSC-mediated effects on RGC survival. We
used two methods of assessing RGC number in our in vivo
model. First, OCT was used to measure the thickness of the
RNFL, which is composed of the axons of the RGCs. These are
lost concomitantly with RGC death and thus provide a means
of monitoring axonal atrophy in real time. Second, Brn3aþ
RGCs in the ganglion cell layer of retinal sections were counted
at 21 dpl, a method that excludes amacrine cells and astrocytes
from the counts.39
OCT recordings showed that in intact animals, RNFL
thickness remained constant over time, whereas after ONC,
RNFL thickness was progressively and significantly reduced.
DPSC or BMSC transplantation resulted in 100% RGC
neuroprotection for up to 7 dpl, but by 14 dpl, significant
neuroprotection was seen only in animals treated with DPSCs.
By 21 dpl, RNFL thickness was decreased in all ONC groups,
suggesting that cell-mediated neuroprotection was failing.
Thus, the OCT data suggest that RGC death was significantly
delayed but not entirely averted. Reasons for the transient
neuroprotective effect of the transplanted cells may be ligand-
mediated downregulation of the TrK receptors14,15 and/or
gradual loss of the grafted cells with concomitant loss of
neurotrophin-mediated protection of RGCs. However, Y
chromosomeþ immunohistochemical staining indicated that
DPSCs persisted in the vitreous of rats 21 days after
transplantation. Further studies are required to analyze in
detail the survival and fate of the transplanted stem cells in the
vitreous of the eye.
Corroborating the OCT results, significantly more Brn3aþ
RGCs were present in the retinae of animals that received
intravitreal transplants of either BMSCs or DPSCs compared
with controls (i.e., untreated animals or those receiving dead
BMSCs/DPSCs). This corroborates the RNFL thickness data,
suggesting that OCT is a valid method for monitoring RGC
survival, although immunocytochemical analysis proves a more
direct as well as a more sensitive approach. RGC survival was
more pronounced in animals receiving DPSCs compared with
those receiving BMSC transplants, correlating with our in vitro
coculture results as well as ELISA data, highlighting higher
titers of neurotrophins produced by the DPSCs. These findings
FIGURE 7. Regeneration of RGC axons in the optic nerve, 21 days after
ONC/cell transplantation. Immunohistochemically stained 15-lm-thick
longitudinal sections of optic nerves, stained for GAP-43 (green) and
laminin (red) 21 days after ONC and DPSC (Ai) or dead DPSC (Aii)
transplantation with the crush site marked by an asterisk. All images
are representative of three sections per nerve, six nerves from six
different animals per treatment group (scale bars: 100 lm). The
number of regenerating axons was measured at 100, 200, 400, 800, and
1200 lm from the ONC site at 21 dpl in untreated animals (purple
bars), animals receiving intravitreal dead DPSC transplants (red dashed
bars), dead BMSCs (blue dashed bars), living BMSCs (blue bars), and
living DPSCs (red bars); black lines indicate significant difference at P
< 0.05. Note GAP-43þ axons outside basal lamina of optic nerve ¼
peripheral innervation of the tissue.
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are also consistent with well-documented data demonstrating
therapeutic short-term effects of injected recombinant neuro-
trophins.10,11
This study provides new evidence that DPSCs are neuro-
protective for RGCs and is supported by the reports of reduced
numbers of apoptotic neurons seen after SCI when DPSCs are
transplanted into the lesion site.21 Three other studies have
shown significant RGC survival after intravitreal cell transplan-
tation. The first two used BMSCs in an animal model of
glaucoma24 and optic nerve transection,23 and the other study
used intravitreally transplanted fibroblasts genetically modified
to express NTF in the same ONC rat model used in this study.16
All these studies showed significant, although short-term, RGC
survival, and attribute this effect to the release of NTF by the
transplanted cells. In particular, it was reported that BMSC
transplantation resulted in RGC survival of 66% compared with
46% in untreated animals at 8 dpl.23 This protection appears
substantially less than that achieved in the current study
(complete protection after 7 days), as assessed by OCT, but can
be explained by the fact that the authors23 transplanted BMSCs
3 days before the ONC, meaning that the RGC counts were
done 11 days after BMSC transplantation. It is likely that the
efficacy of the transplanted cells diminished significantly by 11
days and that the neuroprotective effect was equally dimin-
ished. This also concurs with our findings that the neuropro-
tective effects of the transplanted cells became less
pronounced over time.
The promising neurite outgrowth stimulated by the DPSCs
seen in the in vitro coculture experiments were supported by
the GAP-43þ RGC axon regenerative response seen in the in
vivo ONC experiment. Accordingly, intravitreal transplantation
of DPSCs increased the number of GAP-43þ axons in the
proximal stump, with many crossing the lesion site and
regenerating into the distal optic nerve. As well as more
pronounced axon regeneration through the lesion site, the
distal nerve stump contained significantly more GAP-43þ axons
that persisted for long distances through the putative axon
growth inhibitory environment of the distal optic nerve.
Finally, less lamininþ scar tissue was seen at crush sites
traversed by regenerating axons, which is a well-documented
correlation.6,43 Indeed, in all the DPSC/BMSC-transplanted
animals with regenerating RGC axons, no scar tissue was
present at the lesion site. This phenomenon has been
attributed to secretion of metalloproteinases and plasminogen
by the regenerating axons that block meningeal fibroblast
migration into the wound and degrade scar tissue.6,44 Thus, the
lack of scar tissue is an additional indication of DPSC-induced
RGC axon regeneration.
This study demonstrates the potential therapeutic benefit of
DPSCs to stimulate the growth of axons along the long
nonpermissive distances required to restore neural function.
Our finding also suggests that the regenerating axons were
disinhibited by the DPSC-derived neurotrophins, presumably
through regulated intramembrane proteolysis of inhibitory
receptors and dissolution of chondroitin sulfate proteogly-
cans,45 and corroborates a previous ONC study in which a
significant number of RGC axons regenerated into the distal
optic nerve after intravitreal transplantation of fibroblasts
genetically modified to express FGF-2, BDNF, and NT-3.16 Our
results also support the recent work that concluded that the
transplantation of DPSCs promoted axonal regeneration across
an SCI lesion site.21
It cannot be ruled out, and is not mutually exclusive in the
aforementioned explanation, that the neuroprotective and
neuritogenic/axogenic effects seen in this study are attribut-
able to an indirect interaction between the stem cell–derived
neurotrophins and the bIII-tubulinþ retinal cells mediated by
GFAPþ retinal glia, which also secrete NTF. In addition,
inflammation triggers the release of CNTF from GFAPþ retinal
glia, resulting in RGC neuroprotection and axogenesis.46,47 In
this study, we show glial cell activation 21 days after stem cell
transplantation, which suggests that glia have a role in the
induction of stem cell–directed neuroprotection/axogenesis,
although increased neurotrophin titers in eyes at 21 dpl may be
stem cell–derived, glial-derived, or a combination of both.
Thus, it is possible that upregulation of glial NTF production
contributed to the neuroprotective and axogenic effects seen
after stem cell transplantation.
We report here for the first time that intravitreal BMSCs
promoted a small but significant regeneration of RGC axons,
even at 1200 lm distal to the crush site. Nonetheless, DPSCs
promoted significantly greater regeneration of RGC axons than
did BMSCs, reflecting their elevated neurotrophin secretion
profile and underlining the potential benefit of DPSCs above
other mesenchymal cell sources.
An important future consideration would be to develop a
safe and more sustained delivery mechanism for the cells. In
the present study, cells were injected as a suspension, which
carries with it certain risks, such as migration of the cells into
endogenous tissue and their uncontrolled proliferation. Encap-
sulation of cells in biologically compatible materials for
transplantation into the vitreous has already been shown with
a retinal cell line that had been genetically modified to release
CNTF in both animal models48 and patients.49 Not only did the
encapsulated cells survive for 6 months,49 but they were also
retrievable. Further studies are ongoing in our laboratory to
develop a similar delivery mechanism for adult human DPSCs.
CONCLUSIONS
We demonstrate here for the first time that DPSCs secrete
multiple neurotrophins that were at least in part responsible
for promoting axotomized RGC neuroprotection and neurito-
genesis/axogenesis, both in vitro and in vivo. DPSCs were more
effective than BMSCs, which is likely due to the higher titers of
neurotrophin secretion by the DPSCs. DPSCs may be a
promising alternative for a CNS regenerative cell therapy.
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